Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
J. Clin. Oncol 2019 Nov 19;[EPub Ahead of Print], K Draaisma, A Chatzipli, M Taphoorn, M Kerkhof, A Weyerbrock, M Sanson, A Hoeben, S Lukacova, G Lombardi, S Leenstra, M Hanse, R Fleischeuer, C Watts, J McAbee, N Angelopoulos, T Gorlia, V Golfinopoulos, JM Kros, RGW Verhaak, V Bours, MJ van den Bent, U McDermott, PA Robe, PJ FrenchFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.